Open AccessComparison of the use of Solidago chilensis (Arnica) and low-level laser therapy for the prevention of oral mucositis in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy
Author(s) -
Ana Cristina Lopes,
Giovana Ferreira Gonçalves,
Anna Cecília Dias Maciel Carneiro,
André Luiz Pantoja dos Santos,
Frederico Nobrega Tomas,
Leonardo Rodrigues de Oliveira,
Karina F. Devienne,
Virgínia Oliveira Crema
Publication year - 2021
Publication title -
research, society and development
Language(s) - English
Resource type - Journals
ISSN - 2525-3409
DOI - 10.33448/rsd-v10i14.22128
Subject(s) - mucositis , medicine , chemotherapy , radiation therapy , toxicity , adverse effect , head and neck cancer , gastroenterology , side effect (computer science) , pharmacology , surgery , computer science , programming language
The oral mucositis is an adverse event of radiotherapy and/or high toxicity chemotherapy. The Solidago chilensis (Arnica) has been used for its antiseptic, analgesic, healing and anti-inflammatory properties. Objective: The purpose of this study was to evaluate the uses of Arnica for oral mucositis prevention in patients submitted to radiotherapy for head and neck tumors treatment and/or high toxicity chemotherapy. Methodology: The determination of the cytotoxicity index of the aqueous extract was determined in vitro. The oral mucosa was evaluated in days 0, 10 and 14 of patients in the groups: treated with lasertherapy (L, n=18), treated with Arnica (A, n=24) and, treated with lasertherapy associated with Arnica (LA, n=4). It was considered significant p<0.05. Results: It was determined IC50=90,74 μg/mL of Arnica’s aqueous extract in SCC-4 cells. The development of oral mucositis was associated with the type of treatment for oral mucositis prevention: L, A, and LA (χ2 = 24,72, p<0.0001). The level of oral mucositis had significant interaction with the type of prevention treatment [F(2) = 9.545, p<0.0001] and, within 14 days [F(2) = 11.995, p<0.0001]. Conclusions: The results obtained suggest which the use of Solidago chilensis (Arnica) can be an important therapeutic option for treatment with low-level laser therapy for oral mucositis prevention in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy.